Rezolute, Inc.
RZLT · NASDAQ
Bulios Fair Price
$2.42
42.7% downside
Current Price
$4.22
According to Bulios Fair Price, RZLT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Rezolute, Inc. (RZLT) is a biotechnology company specializing in the development of therapeutics to improve the lives of patients suffering from metabolic disorders and endocrine disorders. Headquartered in the United States, the company focuses on researching and developing new treatment approaches and therapies for patients with type 1 diabetes and other health issues. The company concentrates on innovations in pharmacology and therapeutic methods, working to create new drugs that can enhance the quality of life for affected patients. Shares of Rezolute, Inc. (RZLT) can be an appealing choice for investors seeking investment opportunities in the biotechnology and healthcare research sector.
Sector
Healthcare
Industry
Biotechnology
CEO
Nevan Charles Elam
Employees
68
Headquarters
Redwood City
Upcoming events
Earnings
Upcoming earnings report
Earnings
Upcoming earnings report